Radioactive 'Smart Bomb' targets Hard-to-Treat tumors
NCT ID NCT05153772
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a drug called 212Pb-DOTAMTATE, which delivers radiation directly to neuroendocrine tumor cells. It includes 69 adults whose tumors have grown despite standard treatments. The goal is to see if the drug shrinks tumors and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
212Pb-DOTAMTATE (a radioactive drug that targets tumor cells)
What this could lead to
If successful, this could offer a new treatment option for people with neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong
This is a mid-stage trial with only 69 participants, so results may not apply to everyone. The treatment involves radiation, which can cause side effects like damage to healthy tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, 77042, United States
-
Louisiana State University (LSU) Health Sciences Center - New Orleans
Metairie, Louisiana, 70006, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Rocky Mountain Cancer Center
Denver, Colorado, 80218, United States